ECP
OACC

Empyrean Capital Partners’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Empyrean Capital Partners’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.63M Hold
900,000
– – 0.32% 83
2026
Q1 		$9.56M Hold
900,000
– – 0.31% 85
2025
Q4 		$9.52M Buy
900,000
+150,000
+20% +$1.59M 0.33% 69
2025
Q3 		$7.88M Buy
+750,000
New +$7.84M 0.32% 59

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Empyrean Capital Partners's OACC Position: Q2 2026 in Review

Empyrean Capital Partners held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q2 2026 at 900,000 shares worth $9.63M. The position accounts for 0.32% of the portfolio, ranked #83.

Empyrean Capital Partners first reported a position in OACC in Q3 2025 and has held it in 4 quarters since. 50 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • Empyrean Capital Partners held 900,000 shares of Oaktree Acquisition Corp III Life Sciences worth $9.63M as of Q2 2026.
  • Empyrean Capital Partners left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q2 2026.
  • Oaktree Acquisition Corp III Life Sciences made up 0.32% of Empyrean Capital Partners's portfolio in Q2 2026, its #83 holding.
  • Empyrean Capital Partners first reported a position in Oaktree Acquisition Corp III Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 50 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on Empyrean Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.